The PIONEER Program
consists of multiple registrational trials to investigate Privosegtor, a neuroprotective candidate, as a potential treatment for acute optic neuropathies with the PIONEER-1 trial starting in optic neuritis (ON).
Learn about the PIONEER-1 and
PIONEER-2 clinical trials in optic neuritis
Optic Neuritis (ON) is an acute inflammation of the optic nerve that can lead to permanent visual impairment. It is a rare condition affecting up to 8 in 100,000 people worldwide with a U.S. incidence estimated to be >30,000 and often represents the first sign of multiple sclerosis.1,2
While corticosteroids are used to treat inflammation in ON, there are no approved neuroprotective therapies that can preserve retinal ganglion cells and the optic nerve and therefore restore vision for patients suffering from optic neuritis.
nerve and therefore restore vision for patients suffering from optic neuritis. Oculis is developing Privosegtor, a novel investigational neuroprotective drug candidate, to help address the unmet medical needs in optic neuritis and other neuro-ophthalmology conditions.
PIONEER-1 and PIONEER-2 are registrational trials to investigate Privosegtor for the treatment of ON.
Oculis is not responsible for the content of any third-party sites or resources, and cannot guarantee the quality of information or support provided.
Privosegtor is an investigational drug candidate and has not been approved by the FDA. Safety and efficacy of Privosegtor for optic neuritis have not been established.
References
1. Martínez-Lapiscina EH, et al. (2014): Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain) 2008-2012. J Neurol. 2014 Apr; 261(4): 759-767 2. Weidong Gu et al. (2023) Incidence of Optic Neuritis and the Associated Risk of Multiple Sclerosis for Service Members of U.S. Armed Forces, Military Medicine, vol. 188, March/April 2023